来源: Pharmaceutical Technology
The collaboration will focus on the development of UCB’s UCB6114 and UCB4594 investigational antibody candidates. Credit: Tatiana / Pixabay. 来源: Pharmaceutical Technology
Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. PepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. 来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Mimotopes Thematic privacy policy
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Whitepaper.
The clinical development partnership will focus on the development of UCB6114 and UCB4594 investigational antibody candidates. It will combine Cancer Research UK’s oncology-focused translational research and clinical development capabilities and the antibody discovery expertise of UCB. If the clinical trials are successful, these candidates might have the potential to provide access to new targeted treatment options for cancer patients.
The potential first-in-class antibody UCB6114 targets a glycoprotein secreted by the tumour stroma, gremlin-1. UCB4594 targets the immune checkpoint, human leukocyte antigen G, which is also called HLA-G. Under the partnership, the Centre for Drug Development of Cancer Research UK will appoint the chief clinical and scientific investigators.
It will also lead the design, preparation, funding, and delivery of Phase I/II studies for both candidates, while UCB will continue their manufacturing. UCB will also be responsible for completing the ongoing UCB6114 clinical study (ONC001) and performing other supporting works. UCB chief scientific officer Dhaval Patel said: “UCB’s strong research productivity together with our antibody expertise and desire to better understand and target the drivers of disease, has resulted in two novel and potentially disruptive candidates in oncology. “As these candidates move forward, we are happy to enter this collaboration with Cancer Research UK, where they will bring world-leading oncology expertise and access to a large network of clinical oncologists who can enable the clinical trials.” The company will retain exclusive rights for further development and commercialisation of both candidates and obtain a licence for the clinical trial results from Cancer Research UK.
In return, UCB will make undisclosed success-based milestones and royalty payments to Cancer Research UK. Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
PepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. 来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Mimotopes Thematic privacy policy
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Whitepaper.